Cargando…

Histone Deacetylase Inhibitors Induce Epithelial-to-Mesenchymal Transition in Prostate Cancer Cells

Clinical experience of histone deacetylase inhibitors (HDACIs) in patients with solid tumors has been disappointing; however, the molecular mechanism of treatment failure is not known. Therefore, we sought to investigate the molecular mechanism of treatment failure of HDACIs in the present study. We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kong, Dejuan, Ahmad, Aamir, Bao, Bin, Li, Yiwei, Banerjee, Sanjeev, Sarkar, Fazlul H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3443231/ https://www.ncbi.nlm.nih.gov/pubmed/23024790 http://dx.doi.org/10.1371/journal.pone.0045045

Ejemplares similares

Epithelial to Mesenchymal Transition Is Mechanistically Linked with Stem Cell Signatures in Prostate Cancer Cells
por: Kong, Dejuan, et al.
Publicado: (2010)

Cancer Stem Cells and Epithelial-to-Mesenchymal Transition (EMT)-Phenotypic Cells: Are They Cousins or Twins?
por: Kong, Dejuan, et al.
Publicado: (2011)

Targeting Bone Remodeling by Isoflavone and 3,3′-Diindolylmethane in the Context of Prostate Cancer Bone Metastasis
por: Li, Yiwei, et al.
Publicado: (2012)

Hypoxia Induced Aggressiveness of Prostate Cancer Cells Is Linked with Deregulated Expression of VEGF, IL-6 and miRNAs That Are Attenuated by CDF
por: Bao, Bin, et al.
Publicado: (2012)

Induction of Cancer Cell Death by Isoflavone: The Role of Multiple Signaling Pathways
por: Li, Yiwei, et al.
Publicado: (2011)

Targeting MicroRNAs for Personalized Cancer Therapy
por: Li, Yiwei, et al.
Publicado: (2013)

Hypoxia-Induced Aggressiveness of Pancreatic Cancer Cells Is Due to Increased Expression of VEGF, IL-6 and miR-21, Which Can Be Attenuated by CDF Treatment
por: Bao, Bin, et al.
Publicado: (2012)

A Histone Deacetylase Inhibitor Suppresses Epithelial-Mesenchymal Transition and Attenuates Chemoresistance in Biliary Tract Cancer
por: Sakamoto, Takuya, et al.
Publicado: (2016)

Up-Regulation of Sonic Hedgehog Contributes to TGF-β1-Induced Epithelial to Mesenchymal Transition in NSCLC Cells
por: Maitah, Ma'in Y., et al.
Publicado: (2011)

The epigenetic modifier trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and epithelial–mesenchymal transition of lens epithelial cells
por: Chen, X, et al.
Publicado: (2013)

Activation of AMP-Activated Protein Kinase by 3,3′-Diindolylmethane (DIM) Is Associated with Human Prostate Cancer Cell Death In Vitro and In Vivo
por: Chen, Di, et al.
Publicado: (2012)

Trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and epithelial–mesenchymal transition in retinal pigment epithelium cells
por: Xiao, Wei, et al.
Publicado: (2014)

Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors
por: Su, Yanrong, et al.
Publicado: (2018)

Metformin and histone deacetylase inhibitor based anti-inflammatory nanoplatform for epithelial-mesenchymal transition suppression and metastatic tumor treatment
por: Jiang, Tianze, et al.
Publicado: (2022)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Activated K-ras and INK4a/Arf Deficiency Cooperate During the Development of Pancreatic Cancer by Activation of Notch and NF-κB Signaling Pathways
por: Wang, Zhiwei, et al.
Publicado: (2011)

Histone Deacetylase Inhibitor Therapy in Epithelial Ovarian Cancer
por: Takai, Noriyuki, et al.
Publicado: (2010)

Histone deacetylase 3 promotes alveolar epithelial–mesenchymal transition and fibroblast migration under hypoxic conditions
por: Jeong, Sung Hwan, et al.
Publicado: (2022)

Inhibition of Histone Deacetylase Impacts Cancer Stem Cells and Induces Epithelial-Mesenchyme Transition of Head and Neck Cancer
por: Giudice, Fernanda S., et al.
Publicado: (2013)

Histone deacetylase 6 inhibition counteracts the epithelial–mesenchymal transition of peritoneal mesothelial cells and prevents peritoneal fibrosis
por: Xu, Liuqing, et al.
Publicado: (2017)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Requirement of Histone Deacetylase 6 for Interleukin-6 Induced Epithelial-Mesenchymal Transition, Proliferation, and Migration of Peritoneal Mesothelial Cells
por: Shi, Yingfeng, et al.
Publicado: (2021)

Anti-Tumor Activity of a Novel Compound-CDF Is Mediated by Regulating miR-21, miR-200, and PTEN in Pancreatic Cancer
por: Bao, Bin, et al.
Publicado: (2011)

Histone deacetylase inhibitors reinforce the phenotypical markers of breast epithelial or mesenchymal cancer cells but inhibit their migratory properties
por: Wawruszak, Anna, et al.
Publicado: (2019)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Histone deacetylase inhibitors promote epithelial-mesenchymal transition in Hepatocellular Carcinoma via AMPK-FOXO1-ULK1 signaling axis-mediated autophagy
por: Xiao, Qiang, et al.
Publicado: (2020)

The Role of Histone Variants in the Epithelial-To-Mesenchymal Transition
por: Lone, Imtiaz Nisar, et al.
Publicado: (2020)

Short-term stimulation with histone deacetylase inhibitor trichostatin a induces epithelial-mesenchymal transition in nasopharyngeal carcinoma cells without increasing cell invasion ability
por: Shen, Zhihua, et al.
Publicado: (2019)

Histone deacetylase 9 promotes endothelial-mesenchymal transition and an unfavorable atherosclerotic plaque phenotype
por: Lecce, Laura, et al.
Publicado: (2021)

Regulation of endothelial-to-mesenchymal transition by histone deacetylase 3 posttranslational modifications in neointimal hyperplasia
por: Chen, Lifang, et al.
Publicado: (2023)

Histone deacetylase inhibitors in multiple myeloma
por: Deleu, Sarah, et al.
Publicado: (2009)

Histone deacetylase inhibitors in Hodgkin lymphoma
por: Buglio, Daniela, et al.
Publicado: (2010)

Clinical Toxicities of Histone Deacetylase Inhibitors
por: Subramanian, Srividya, et al.
Publicado: (2010)

Acetylation and Histone Deacetylase Inhibitors in Cancer
por: Kortenhorst, Madeleine S. Q., et al.
Publicado: (2006)

Histone Deacetylase Inhibitors as Anticancer Drugs
por: Eckschlager, Tomas, et al.
Publicado: (2017)

The application of histone deacetylases inhibitors in glioblastoma
por: Chen, Rui, et al.
Publicado: (2020)

Histone Deacetylases and Their Inhibitors in Cancer Epigenetics
por: Hassell, Kelly N.
Publicado: (2019)

New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma
por: Wedel, S A, et al.
Publicado: (2008)

Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer
por: Pramanik, Siddhartha Das, et al.
Publicado: (2022)

Nanotechnology-Based Histone Deacetylase Inhibitors for Cancer Therapy
por: Tu, Bin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qgcnjonr77asfjomnajr18tinf